BACKGROUND: Mucosal melanomas in the head and neck region are most often located in the nasal cavity and paranasal sinuses. To the authors' knowledge, the prognostic effects of lymph node metastasis in patients with sinonasal mucosal melanoma (SNMM) have not been established. Therefore, the objective of the current study was to determine the effects of lymph node metastasis on survival. METHODS: The current study included 198 patients with SNMM who had been treated between 1985 and 2016 at The University of Texas MD Anderson Cancer Center in Houston. Patients' clinical and pathologic lymph node statuses were evaluated and characterized. A multivariate analysis was used to assess the associations between regional spread and survival outcomes. RESULTS: Therapeutic neck dissection was performed in 23 patients with SNMM (11.6%). Regional disease recurrence occurred in 7 of the patients who had lymph node metastasis at the time of presentation (30.4%) and in 30 of those who had N0 disease at the time of presentation (17.1%) (P 5.15). Metastasis to the contralateral lymph nodes was present in 7 patients (3.5%). The 5-year disease-specific survival rate was 66% in patients with lymph node spread compared with 45% in patients with N0 status (P 5.04, log-rank test). A multivariate analysis demonstrated that distant metastasis was the only variable found to be independently associated with both overall survival (hazard ratio, 2.96; 95% confidence interval, 1.54-6.95 [P 5.01]) and disease-specific survival (hazard ratio, 3.32; 95% confidence interval, 1.79-7.14 [P 5 0.01]). CONCLUSIONS: The results of the current study demonstrated that lymph node status in patients with SNMM was not a significant predictor of outcome. This finding, together with the low incidence of lymph node metastases in patients with SNMM, suggests that elective treatment of the neck should be highly selective in this patient population.
INTRODUCTION
Mucosal melanoma can occur on any mucosa-lined body surface. Head and neck mucosal melanomas account for 50% to 55% of all mucosal melanomas, with the most common site being the nasal or paranasal cavity. 1, 2 Despite this, sinonasal mucosal melanoma (SNMM) is considered rare, accounting for 1% of all melanomas. 3 SNMM is a uniformly aggressive tumor, with 5-year overall survival (OS) rates of 20% to 35%. 3 However, at the time of presentation, only 10% to 20% of patients have clinically detectable lymph node disease. 2 Regional disease is of great importance in determining disease prognosis and treatment in patients with cutaneous melanoma. To the best of our knowledge, the presence of lymph node disease is the most powerful predictor of early-stage disease. 4 Increasing attention has been given to the importance of the early microscopic detection of regional disease using sentinel lymph node biopsy. Regional disease, even when microscopic, results in an increased disease stage and patients may require more intensive treatment. 5 Treatment of the neck in patients with sinonasal tumors remains controversial. Tumors of the ethmoid sinuses rarely present or recur in the neck, and the National Comprehensive Cancer Network guidelines for head and neck cancer recommend against elective neck dissection. 6, 7 To the best of our knowledge, guidelines regarding other nasal and paranasal sinus sites are less well defined. To add to this complexity, the likelihood of lymph node disease also depends on the tumor's pathological characteristics. 6 SNMM represents only 4% of sinonasal malignancies, and therefore is underrepresented in studies investigating regional metastasis according to the anatomic site of the tumor. 3 To our knowledge, the prognostic effects of lymph node metastasis in patients with SNMM are unclear. Therefore, in the current retrospective study, we quantified regional disease in patients with SNMM, identified risk factors for lymph node metastasis, and determined the effects of lymph node metastasis on survival.
MATERIALS AND METHODS
Institutional review board approval was obtained before the start of the current study (protocol RCR04-0636). Written informed consent was waived because all of the patients had undergone treatment that was consistent with the current standard of care. We reviewed the records of all consecutive patients who had been treated at The University of Texas MD Anderson Cancer Center in Houston between August 1985 and July 2016 and who met the following inclusion criteria: 1) pathologically diagnosed with mucosal melanoma; 2) the sinonasal cavity was the primary tumor site; and 3) preoperative neck imaging was performed, including computed tomography, positron emission tomography-computed tomography, or magnetic resonance imaging.
We identified 198 patients who met the inclusion criteria. None of these patients had undergone sentinel lymph node biopsy. Patient demographics (age, sex, date of diagnosis, smoking history, and alcohol intake), stage of disease, tumor characteristics, treatment modalities, skull base invasion status, pathologic data (surgical margin status, tumor thickness, ulceration, perineural and lymphovascular invasion, bony invasion, and number of mitotic figures), and clinical outcomes were collected from patient records. All staging was completed according to the guidelines of the seventh edition of the American Joint Committee on Cancer staging system. 5 Cases that had been staged before the release of the seventh edition of American Joint Committee on Cancer classification system in 2010 were reclassified. Staging changed in 71 of the 111 patients treated before 2010.
The primary outcome measure was the incidence of lymph node metastasis. The location of the lymph node metastasis (ie, ipsilateral [levels I-III, parotid, and retropharyngeal] or contralateral [level I or II] lymph nodes) was categorized according to the neck level, as described by the American Head and Neck Society. 8 Secondary outcomes included OS, disease-specific survival (DSS), disease-free survival (DFS), regional recurrence-free survival, and distant metastasis-free survival. The index date for all survival outcomes was the date of initiation of the first modality of treatment. DFS was defined as the time from the index date to the date of evidence of disease after the completion of primary treatment.
Statistical Analysis
Basic baseline descriptive statistics were generated. Continuous data were compared using the Student t test, and categorical variables were compared using the chi-square test. The Kaplan-Meier method was used for all survival analyses. Survival outcomes were compared in those patients undergoing neck dissection and those not undergoing neck dissection using the log-rank test. Univariate and multivariate analyses, performed using the Cox proportional hazards model, were used to identify clinicopathologic risk factors for OS and DSS. All statistical testing was 2-tailed. The alpha was set to .05 for statistical significance.
The sample size of 198 patients for the current analysis was not based on predetermined power calculations; it had 80% power to detect a hazard ratio (HR) of 1.54 for the effects of positive lymph node status on OS and 80% power to detect an HR of 1.93 for DSS. All statistical testing was completed using SAS JMP Pro software (version 12.1.0; SAS Institute Inc, Cary, North Carolina).
RESULTS
Of the 198 patients included in the current study, 95 (48%) were male and 103 (52%) were female. The median age of the patients was 64 years (range, 34-94 years). The primary tumor epicenter was the nasal cavity in 142 patients (72%) and the paranasal sinuses in 56 patients (28%). Invasive disease (defined as T4a-T4b disease) was present in 82 patients (41%).
Eleven patients had undergone surgery before presenting to the study institution. None of these patients had received radiotherapy or systemic therapy. Distant metastasis was evident in 14 patients (7%) at the time of presentation; these patients had undergone systemic treatment, with no surgery performed. Adjuvant radiotherapy was administered in 105 patients (53%). All patients who presented with lymph node disease (23 patients) received radiotherapy to both the primary tumor bed and the involved neck. Elective ipsilateral neck irradiation was used in 10 patients, and 2 patients had undergone elective bilateral neck irradiation. Three patients were treated using a hypofractionated regimen (ie, 5 grays per fraction), whereas 32 patients were treated using standard fractionation (ie, 2 grays per fraction). Neoadjuvant chemotherapy was administered to 23 patients (12%) and postoperative concurrent chemotherapy to 11 patients (6%). The neoadjuvant regimen included platinum-based Table 1 presents the clinical and pathological characteristics of the patients in the current study according to lymph node status at the time of presentation. Therapeutic neck dissection was performed in 23 patients with SNMM (11.6%) whose preoperative workups had revealed regional lymph node metastases. Of these patients, 10 patients were classified as having cN1 disease, 6 as having cN2b disease, and 7 as having cN2c disease. Elective neck dissection was performed in 3 patients, none of whom had occult lymph node disease (cN0/pN1). Regional metastases were present in 14 of the 142 patients with nasal cavity tumors (9.9%) compared with 9 of the 56 patients with paranasal sinus SNMM (16.1%) (P 5 .22). Regional metastases were present in 18 of the 102 patients aged < 65 years (17.6%) and 5 of the 96 patients aged > 65 years (5.2%) (P 5 .007). At the time of initial presentation, there was no correlation between lymph node metastases and other pathological features (Table 1) . Regional disease recurrence occurred in 7 of the patients who had lymph node metastasis at the time of presentation (30.4%) and 30 of those who had N0 disease at the time of presentation (17.1%) (P 5 .15) (Fig. 1) . There was no significant difference in the regional disease recurrence rates observed between patients with N0 disease who had undergone elective neck irradiation and those who had not (17% vs 18%; P 5 .65) (Fig. 1) .
Regional Patterns of Spread in Patients With SNMM
To characterize the patterns of lymphatic drainage, we analyzed the involved neck levels in patients who had undergone therapeutic neck dissection, both at the time of presentation and at disease recurrence. Histologically confirmed lymph node metastases were detected in 60 neck dissection specimens from 53 patients (26.7%). The involved lymph node echelon was ipsilateral level I in 30 patients (56.6%), ipsilateral level II in 19 patients (35.8%), and the retropharyngeal lymph nodes in 6 patients (11.3%). The ipsilateral parotid lymph nodes were involved in 2 patients (3.7%) and 2 other patients (3.7%) had ipsilateral level III disease. Metastasis to the contralateral lymph nodes was present in 8 patients (15.1%) (5 with level I disease and 3 with level II disease).
Supporting Information Table 1 shows the incidence of neck metastases in patients who had undergone therapeutic neck dissection according to the primary tumor site. Level I disease was found in 24 of 43 patients in whom the nasal cavity was the primary tumor site (55.8%) compared with 6 of 10 patients (60%) for whom the paranasal sinus was the primary tumor site (P 5 .45). However, the retropharyngeal lymph nodes were involved in in 3 of 43 patients in whom the nasal cavity was the primary tumor site (7%) compared with 3 of 10 patients (30%) for whom the paranasal sinus was the primary tumor site (P 5 0.07). Figure 2 shows the Kaplan-Meier curves of patient outcomes according to the pathological lymph node status. The 5-year OS rate was 37% in patients with lymph node spread compared with 43% in patients with N0 disease (P 5 .4). The 5-year DSS rate was 66% in patients with lymph node spread compared with 45% in patients with N0 disease (P 5 .04).
The overall rate of disease recurrence was 62.1% (123 of 198 patients). A total of 37 patients (18.7%) had regional disease recurrence; of these patients, 16 had simultaneous distant metastasis or uncontrolled local disease recurrence. Surgical neck salvage was achieved in 21 patients who had no evidence of distant spread; of those, 14 patients underwent irradiation for disease recurrence. Among patients with lymph node metastases, the 5-year DFS rate was 43% compared with 44% for patients without lymph node disease (P 5 .86) (Fig. 3) . The 5-year regional recurrence-free survival rate in patients with pN 1 disease was 78% compared with 82% in those with no lymph node disease at the time of presentation (P 5 .69). The 5-year distant metastasis failure rates were 45% and 43%, respectively, in patients with and without lymph node metastasis (P 5 .99).
Independent Predictors of Outcome
We first performed a univariate analysis to identify the variables that were significantly associated with OS and DSS. Variables that were found to be significant on univariate analysis were introduced into a multivariate model. A multivariate analysis then was used to evaluate the effect of these clinicopathological variables on outcome. T classification, lymph node metastasis, distant metastasis, bone invasion, skull base invasion, surgical margin status, ulceration, mitosis rate, and treatment group were found to be significant predictors of survival on univariate analysis and were used in the multivariate model. As shown in Table 2 , the only variable that was found to be independently associated with both OS (HR, 2.96; 95% confidence interval, 1. Table 2 ).
DISCUSSION
In patients with mucosal melanoma, surgical resection with clear margins remains the treatment of choice, often accompanied by postoperative radiotherapy. Treatment of the regional lymphatics should be based on the presence of clinically detectable involved lymph nodes. To the best of our knowledge, existing data regarding the incidence of SNMM lymph node metastases and their effect on outcome are insufficient to determine whether elective treatment of the neck is advisable in the management of these patients. In the current study, we reported that the incidence of neck metastasis in patients with SNMM at the time of presentation was 11%; this was considerably lower than that in patients with mucosal melanoma of the oral cavity and squamous cell carcinoma of the head and neck. [9] [10] [11] [12] However, the pattern of lymphatic metastasis was similar to that of squamous cell carcinoma and reflects the expected lymphatic drainage echelons of the sinonasal cavity. 13, 14 Although therapeutic neck dissection is performed routinely in all patients with clinical evidence of lymph node metastases, the decision to perform an elective neck dissection is complicated by the limited ability of imaging techniques to assess occult cervical metastases that might become apparent later in the disease course. 15 Elective neck dissection is not routinely performed among patients with SNMM at the study institution and therefore we could not formulate the rate of occult metastasis. However, the data from the current study demonstrate an overall 30% risk for neck metastases in patients with SNMM. In patients with head and neck squamous cell carcinoma, elective neck dissection is indicated if the probability of occult cervical metastases is >15% to 20% because the presence of neck metastases is the single most significant predictor of outcome. 16 For patients with mucosal melanoma in general, involvement of the lymph nodes affects survival considerably. 11 In agreement with previously published studies, 12, 17, 18 we found that lymph node status in patients with SNMM was not associated with the rate of disease recurrence, distant metastasis, or survival. Furthermore, the regional control rates were not found to be associated with lymph node status at the time of initial presentation. We found no significant improvement in regional recurrence rates in patients with N0 disease who had undergone elective lymph node irradiation; given the significant toxicity associated with neck irradiation, these findings further support the limited role of elective treatment of the neck in patients with SNMM.
To the best of our knowledge, the current study represents the largest published series of patients with SNMM treated at a single institution published to date. However, because of the retrospective design of the current study, no data regarding the neck radiotherapy fields could be retrieved. Nevertheless, the data from the current study suggest that lymph node metastases are most commonly found at levels I to III and retropharyngeal sites. Furthermore, the low rate of contralateral neck metastases noted herein (15%) suggests that neck treatment should include levels I to III on the ipsilateral side; if the tumor originates from the paranasal sinuses, the retropharyngeal lymph nodes should be addressed as well. Consequent to the retrospective design of the current study, the medical records may reflect heterogeneity in reporting between providers (eg, pathologists, radiologists, and radiation oncologists). We realize that treatment also may vary among different institutions. All patients with SNMM treated at The University of Texas MD Anderson Cancer Center, a high-volume center, are evaluated by a multidisciplinary team that includes a head and neck surgeon and radiation and medical oncologists. When needed, neurosurgeons, ophthalmologists, and reconstructive surgeons are consulted. For patients with localized disease (ie, T3 and T4a), surgical resection with negative surgical margins is the main treatment modality. Neck dissection usually is performed only for patients with positive lymph node disease. Adjuvant radiotherapy to the primary tumor is administered to patients with locally advanced disease (ie, skull base, bone, dura, brain, eye, or palate), paranasal sinus involvement, and adverse pathological features (eg, positive surgical margins, perineural invasion, or lymphatic spread). The neck field is included in the macroscopic total volume only in the case of positive neck lymph nodes.
Because of the small number of individuals in the current study who underwent elective neck dissection and sentinel lymph node biopsy, we were unable to evaluate the incidence of occult lymph node metastasis and the effect of these procedures on survival. Until such data are Abbreviations: 95% CI, 95% confidence interval; CRT, chemoradiotherapy; DSS, disease-specific survival; HR, hazard ratio; OS, overall survival; RT, radiotherapy; SNMM, sinonasal mucosal melanoma.
available, the treatment of patients with SNMM should be based on the risk stratification of each patient and on the decisions of the multidisciplinary teams that manage their treatment.
Conclusions
The results of the current study demonstrate that throughout the disease course, the incidence of neck metastasis in patients with SNMM was not low, as reported for other sites in the head and neck. However, in a multivariate analysis, lymph node status was not found to be a significant predictor of outcome. This finding suggests that elective treatment of the neck is not indicated in this patient population.
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